KITOV PHARMA LT/S (NASDAQ:KTOV) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $1.60 and last traded at $1.68, with a volume of 2461 shares. The stock had previously closed at $1.90.

A number of equities research analysts have issued reports on KTOV shares. Zacks Investment Research upgraded shares of KITOV PHARMA LT/S from a “sell” rating to a “hold” rating in a research note on Friday, June 15th. HC Wainwright reiterated a “buy” rating and set a $12.50 price objective on shares of KITOV PHARMA LT/S in a research note on Tuesday, June 19th.

The firm has a market capitalization of $30.57 million, a P/E ratio of -1.28 and a beta of 2.34.


Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.

Featured Article: Earnings Per Share (EPS) Explained

Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with's FREE daily email newsletter.